Analyst Price Targets — FTH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 25, 2026 8:15 pm | Jack Allen | Robert W. Baird | $57.00 | $24.67 | TheFly | Faeth Therapeutics initiated with an Outperform at Baird |
| June 22, 2026 10:00 am | — | H.C. Wainwright | $60.00 | $17.82 | TheFly | Faeth Therapeutics initiated with a Buy at H.C. Wainwright |
| May 28, 2026 11:06 am | Christopher Liu | Loop Capital Markets | $50.00 | $16.65 | StreetInsider | Lucid Capital Markets Starts Sensei Biotherapeutics (SNSE) at Buy |
| May 13, 2024 4:20 pm | Sudan Loganathan | Stephens | $5.00 | $1.57 | TheFly | Sensei Biotherapeutics initiated with an Overweight at Stephens |
| December 13, 2022 1:13 pm | — | Citigroup | $6.00 | $1.74 | Benzinga | Citigroup Initiates Coverage On Sensei Biotherapeutics with Buy Rating, Announces Price Target of $6 |
Latest News for FTH
Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth's Board of Directors granted six new employees options to purch
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth's Board of Directors granted six new employees options to purchase an aggregate of 180,350 shares of the Company's common stock in connection with their employment (collectively, the “Option Awards”). The Option Awards were granted pursuant to the Company's 2026 Inducement Plan as a…
AUSTIN, Texas--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that it has changed its corporate name to Faeth Therapeutics, Inc. (the “Company”). The Company's common stock is expected to begin trading on the Nasdaq Capital Market under the new ticker symbol “FTH” on June 16, 2026, and the Company has launched a new corporate website at www.faeththerapeutics.com. On June 10, 2026,…
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on June 1, 2026, the Compensation Committee of Sensei's Board of Directors granted
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on June 1, 2026, the Compensation Committee of Sensei's Board of Directors granted three new employees options to purchase an aggregate of 19,300 shares of the Company's common stock in connection with their employment (collectively, the “Option Awards”). The Option Awards were granted pursuant to the Company's 2026…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for FTH.
U.S. House Trading
No House trades found for FTH.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.